



16

#36/D CW
DM
01/21/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99-369)

PATENT

In re Application of: Brewer et al.

Serial No.: 08/484,337

Filed: June 7, 1995

For: Tumor Necrosis Factor (TNF)
Inhibitor and Method
for Obtaining Same

Before the Examiner:
E. Lazar Wesley

Group Art Unit: 1647

Box ISSUE FEE
Commissioner for Patents
Washington, D.C. 20231

OK to Enter

Sir:

AMENDMENT UNDER 37 C.F.R. § 1.312

Applicants respectfully request that the following additional amendments be entered prior to issuance of the above-described patent application pursuant to 37 C.F.R. § 1.312(b).

In the Specification:

Please amend the section at page 5, line 15 to page 9, line 37 to read as follows:

Figure 1 describes a cytotoxicity assay for TNF in the absence (-.-) and in the presence (-x-x-) of TNF inhibitor (30kDa). Various concentrations of TNF were incubated with and without TNF inhibitor, and the cytotoxicity assay was performed as described in Example 1.

Figure 2 describes a native gel shift assay in which "a" depicts TNF alone, and "b" depicts TNF + TNF inhibitor (30kDa).

Figure 3 describes Con A-Peroxidase staining of TNF inhibitor (30kDa). About 200 ng of each protein were run on 14% SDS-PAGE, and transferred to nitrocellulose filter. Glycoproteins were identified using Con A-peroxidase staining. In this figure, "a" depicts a molecular weight marker, "b" depicts Ovalbumin, "c" depicts bovine serum albumin, and "d" depicts TNF inhibitor.

Figure 4 describes chemical deglycosylation of TNF inhibitor (30kDa). About 200 ng